Table 6.
Projected prevalence and number of people living with age–related macular degeneration (AMD) in China from 2020 to 2050, by AMD type
| AMD type |
Prevalence of AMD (%, 95% CI) |
Number of people with AMD (million, 95% CI) |
Rate of change (%, 2020–2050) |
|||
|---|---|---|---|---|---|---|
|
2020 |
2050 |
2020 |
2050 |
prevalence |
AMD cases |
|
| Any AMD |
5.39 |
7.64 |
31.23 |
55.19 |
41.66 |
76.72 |
| (4.18–6.93) |
(5.96–9.73) |
(24.18–40.14) |
(43.04–70.30) |
|||
| Early AMD |
4.23 |
5.85 |
24.47 |
42.26 |
38.45 |
72.71 |
| (3.47–4.99) |
(4.87–6.79) |
(20.10–28.87) |
(35.15–49.05) |
|||
| Late AMD |
1.17 |
1.79 |
6.76 |
12.92 |
53.28 |
91.21 |
| (0.70–1.95) |
(1.09–2.94) |
(4.08–11.28) |
(7.89–21.26) |
|||
| GA |
0.39 |
0.57 |
2.26 |
4.09 |
44.92 |
80.78 |
| (0.18–0.83) |
(0.26–1.19) |
(1.04–4.78) |
(1.89–8.59) |
|||
| NVAMD | 0.78 |
1.22 |
4.50 |
8.84 |
57.48 | 96.45 |
| (0.52–1.12) | (0.83–1.75) | (3.04–6.50) | (6.00–12.66) | |||
GA – geographic atrophy, NVAMD – neovascular AMD